Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Guardant Health’s 10-K can feel like wading through both biotech jargon and accounting footnotes. Key details on liquid biopsy test volumes, FDA submissions, and R&D burn rates are scattered across hundreds of pages, while Form 4 insider sales from the founders often appear without context. If you have ever searched “Guardant Health SEC filings explained simply” or asked, “Where can I find the Guardant Health quarterly earnings report 10-Q filing?”, you know the challenge.
Stock Titan solves it. Our AI-powered summaries translate dense cancer-genomics language into clear insights, flagging segment revenue shifts and clinical milestone disclosures in seconds. Need real-time alerts? The moment a “Guardant Health Form 4 insider transactions real-time” filing hits EDGAR, we surface it alongside easy-to-read charts of executive stock transactions. Drill into any document:
- Guardant Health annual report 10-K simplified – spot test-volume growth and cash runway.
- Guardant Health quarterly earnings report 10-Q filing – track sequential margin changes.
- Guardant Health 8-K material events explained – catch trial results or reimbursement wins.
- Guardant Health proxy statement executive compensation – review R&D-weighted incentive plans.
Whether you’re modeling future oncology revenues or monitoring “Guardant Health earnings report filing analysis” for competitive intelligence, Stock Titan provides AI guidance that saves hours. Join institutional investors who are already “understanding Guardant Health SEC documents with AI” to make informed decisions faster.
Guardant Health, Inc. (GH) – Form 4 filing (07/02/2025)
Chief Information Officer Kumud Kalia reported routine equity transactions tied to the vesting of previously granted restricted stock units (RSUs) on July 1 2025:
- 2,691 common shares were issued upon the automatic conversion of RSUs (Transaction Code M) at a zero exercise price.
- 1,365 shares were simultaneously surrendered to the company to cover statutory tax-withholding obligations (Transaction Code F) at a market price of $50.71.
- After the net share settlement, Kalia’s direct ownership increased by 1,326 shares to a total of 20,500 common shares.
The derivative table shows that the executive still holds 8,035 unvested RSUs from a November 7 2022 grant and 5,419 unvested RSUs from a December 13 2023 grant, each vesting quarterly over their remaining terms. No open-market sales or purchases were reported beyond the withheld shares, indicating that the insider retained all newly vested stock net of taxes.
This filing reflects standard equity-compensation activity; it does not disclose any new option grants, cash transactions, or information that would materially alter Guardant Health’s financial outlook. The scale of the net acquisition is immaterial relative to the company’s total shares outstanding, but it modestly increases insider alignment.
Guardant Health, Inc. (GH) – Form 4 insider transaction, filed 2 Jul 2025
Chief Commercial Officer Chris Freeman reported automatic vesting of two restricted-stock-unit (RSU) tranches on 1 Jul 2025:
- 1,929 shares from a November 2022 RSU grant.
- 1,667 shares from a December 2023 RSU grant.
Both conversions were coded “M” (exempt), reflecting zero exercise price. To cover associated tax obligations, the company withheld 1,532 shares (Code “F”) at a market price of $50.71.
After the transactions, Freeman’s direct ownership rose by a net ≈2,064 shares to 48,821 shares. No open-market purchases or discretionary sales occurred; all movements relate to routine equity compensation vesting and withholding.
On 1 July 2025, Guardant Health, Inc. (GH) filed a Form 4 disclosing routine equity compensation activity by Chief Technology Officer Darya Chudova. Two tranches of previously granted restricted stock units (RSUs) converted into 3,007 common shares at a zero exercise price. To satisfy statutory tax-withholding requirements, 1,525 shares were immediately withheld and disposed of at a market price of $50.71. The net effect is an incremental increase of 1,482 shares, lifting Chudova’s direct beneficial ownership to 81,294 shares.
The derivative table shows Chudova still holds 15,033 unvested RSUs—6,696 from a November 7 2022 grant that vests quarterly through October 2026, and 8,337 from a December 13 2023 grant that vests quarterly through October 2026. Both awards follow typical time-based vesting schedules, and no open-market transactions, 10b5-1 trades, or discretionary sales were reported.
Because the activity stems from standard RSU vesting rather than a voluntary purchase or sale, the filing carries minimal direct market impact. Still, the absence of net selling and the modest increase in insider ownership may be viewed as slightly constructive for investor sentiment.
Guardant Health (GH) – Form 4 filing dated 07/02/2025 discloses routine equity activity by Chief Financial Officer Michael Brian Bell linked to previously granted restricted stock units (RSUs).
- On 07/01/2025, 2,084 RSUs vested (code M). These were converted into common shares at no cash cost.
- To satisfy tax-withholding, 1,057 shares were automatically withheld and disposed of at $50.71 per share (code F).
- Net result: the CFO’s direct common-stock holdings increased by 1,027 shares to 43,028 shares; he retains 10,421 unvested RSUs.
No open-market purchases or discretionary sales occurred; the transactions appear strictly administrative and are consistent with the original three-year vesting schedule of the December 13, 2023 RSU grant.
Guardant Health, Inc. (GH) – Form 4 insider transaction summary for Co-CEO & Director AmirAli Talasaz. The filing covers activity on 06/30/2025 and 07/01/2025.
- Option / RSU exercises (Code M): 4,815 shares were issued on 06/30/2025 and 23,997 shares on 07/01/2025 at a $0 exercise price, representing vested restricted stock units.
- Shares withheld for taxes (Code F): 2,441 shares (avg. $52.04) on 06/30/2025 and 12,162 shares (avg. $50.71) on 07/01/2025 were retained by the company to satisfy withholding obligations.
- Open-market sales (Code S): 72,068 shares sold at a weighted avg. price of $50.6715 (price range $50.08-$51.07) and 27,932 shares sold at a weighted avg. price of $51.4047 (range $51.08-$51.94) on 07/01/2025. All sales were executed under a Rule 10b5-1 trading plan adopted on 12/17/2024.
- Net effect: Beneficial ownership fell from 2,074,271 to 1,983,665 shares, a decrease of 90,606 shares (~4.4% of the prior direct holdings). Derivative holdings now show 9,629 and 143,983 unvested RSUs under two separate awards.
The transactions were routine equity award vesting, tax withholding, and pre-planned sales. No cash was paid for option/RSU exercises, and the filing does not disclose any changes to company fundamentals or guidance.
Form 4 filed for Guardant Health, Inc. (GH) details a routine equity award vesting by director Steve E. Krognes on 06/30/2025. Krognes converted 154 restricted stock units (RSUs)—originally granted on 08/09/2022—into the same number of common shares at a stated price of $0, reflecting a non-cash, in-kind issuance. Following the transaction, he directly owns 17,819 common shares and retains 1,852 unvested RSUs. The RSU grant vests monthly through 06/30/2026, and no shares were sold. The filing signifies ordinary executive compensation activity with no immediate balance-sheet or cash-flow impact on the company.
Form 4 highlights for Guardant Health, Inc. (GH): Co-Chief Executive Officer and Director Helmy Eltoukhy reported two routine RSU vesting events and related tax-withholding sales over 30 June-1 July 2025.
- RSU vesting (Code “M”): 4,815 shares vested on 30 Jun 2025 and 23,997 shares vested on 1 Jul 2025, totalling 28,812 shares acquired at $0 exercise price.
- Tax withholding sales (Code “F”): 2,441 shares sold at $52.04 and 12,162 shares sold at $50.71 to cover payroll taxes, for an aggregate 14,603 shares disposed.
- Net change: Insider’s direct common-stock position rose by 14,209 shares, bringing total direct ownership to 2,423,499 shares. He also continues to hold 143,983 unvested RSUs.
- Derivative section clarifies the vesting schedules: a 4-installment 2025 grant and a previously granted award that vests quarterly over 24 months.
All transactions are routine equity-compensation events; no open-market purchases or discretionary sales were reported. The filing signals ongoing insider equity accumulation and substantial alignment, but does not reveal new operational or financial information about Guardant Health.
Director Tariq Musa of Guardant Health reported multiple transactions on June 18, 2025:
- Sale: Disposed of 3,213 shares of common stock at $49.47 per share, retaining 7,190 shares after the transaction
- Stock Options: Received 6,833 stock options with exercise price of $50.57, expiring June 18, 2035
- RSUs: Granted 4,203 restricted stock units
Both the stock options and RSUs vest in full on the earlier of June 18, 2026, or the date of the next annual stockholders meeting. This filing represents standard equity compensation for a board member, with a simultaneous sale of existing shares. The transaction was executed through an attorney-in-fact, John G. Saia.
Guardant Health Director Myrtle S. Potter reported multiple securities transactions on June 18, 2025:
- Disposed of 26 shares of Common Stock at $49.47 per share, retaining direct ownership of 18,154 shares
- Acquired new stock options for 6,833 shares with exercise price of $50.57, expiring June 18, 2035
- Received 4,203 Restricted Stock Units (RSUs) at $0 cost basis
Both the stock options and RSUs vest in full on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs earlier. The transactions were reported through Form 4 filing, with attorney John G. Saia signing on Potter's behalf on June 20, 2025.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
